Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $1.6 million, down 37.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 37.12% YoY), and the FY2025 annual result was $1.8 million, down 47.18% from the prior year.
• Non-Current Deffered Revenue eased to $1.6 million in Q1 2026 per CRBU's latest filing, from $1.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $18.2 million in Q2 2023 and troughed at $1.6 million in Q1 2026.
• A 5-year average of $6.9 million and a median of $4.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue jumped 741.41% in 2022, then slumped 74.65% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $16.0 million in 2022, then sank by 61.75% to $6.1 million in 2023, then sank by 45.64% to $3.3 million in 2024, then tumbled by 47.18% to $1.8 million in 2025, then dropped by 5.94% to $1.6 million in 2026.
• Business Quant data shows CRBU's Non-Current Deffered Revenue at $1.6 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.